Temporal Trends of Inflammatory Bowel Disease Burden in China from 1990 to 2030 with Comparisons to Japan, South Korea, the European Union, the United States of America, and the World
DOI: https://doi.org/10.2147/CLEP.S402718
2023-05-08
Clinical Epidemiology
Abstract:Tian Ma, 1– 3 Meng Wan, 1– 3 Guanqun Liu, 1– 3 Xiuli Zuo, 1– 3 Xiaorong Yang, 1– 4 Xiaoyun Yang 1– 4 1 Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, People's Republic of China; 2 Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, People's Republic of China; 3 Shandong Provincial Clinical Research Center for Digestive Disease, Qilu Hospital of Shandong University, Jinan, People's Republic of China; 4 Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, People's Republic of China Correspondence: Xiaorong Yang, Clinical Epidemiology Unit, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, 250012, People's Republic of China, Tel +86-531-82166951, Fax +86-531-86927544, Email Xiaoyun Yang, Department of Gastroenterology, Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, People's Republic of China, Tel +86-531-82169034, Fax +86-531-86927544, Email Purpose: To identify and predict the epidemiological burden and trends of inflammatory bowel disease (IBD) in China and compare them globally. Methods: We collected incidence, prevalence, deaths, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and the age-standardized rates (ASRs) of IBD from 1990 to 2019 in China, four developed countries and the world, from the Global Burden of Disease Study 2019. The average annual percentage change (AAPC) was calculated to evaluate the temporal trends. Results: From 1990 to 2019, the numbers of incident and prevalent cases, age-standardized incidence rate (ASIR), and age-standardized prevalence rate (ASPR) of IBD increased in China, regardless of gender and age; decreased YLLs and increased YLDs caused a stable number of DALYs; the age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) decreased. In 2019, the ASIR, ASPR, ASMR, and ASDR were 3.01/100,000 person-years (/100,000) (95% UI: 2.59, 3.50), 47.06/100,000 (95% UI: 40.05, 54.99), 0.30/100,000 (95% UI: 0.24, 0.35), and 13.1/100,000 (95% UI: 10.29, 16.31), respectively; almost all disease burden data were higher in males. In 2017, the ASDR in different socio-demographic index provinces ranged from 24.62/100,000 (95% UI: 16.95, 33.81) to 63.97/100,000 (95% UI: 44.61, 91.48). When compared globally, the ASIR and ASPR in China had opposite trends and the highest AAPCs. In 2019, the ASIR and ASPR in China were in the middle of the world and lower than in some developed countries. The numbers and ASRs of incidence, prevalence, and DALYs were expected to increase by 2030. Conclusion: The IBD burden in China significantly increased from 1990 to 2019 and was expected to rise further by 2030. China had the world's opposite and most dramatic trends in ASIR and ASPR from 1990 to 2019. Strategies should be adjusted to adapt to the significantly increased disease burden. Keywords: inflammatory bowel disease, China, disease burden, temporal trend, projection Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is an incurable disease with a chronic relapsing course. 1,2 This disease most commonly occurs in young and middle-aged adults. 3,4 Despite recent advances in treatment, IBD still has a certain mortality rate and a high disability rate. 5,6 Data from follow-up studies showed that most IBD patients had intestinal or extra-intestinal complications, such as strictures, perforations, fistulas, abscesses, and thrombosis, throughout the course of the disease. 7–9 Life-time surgery rates are generally 50% for CD and 20–30% for UC. 1,2 The risk of postoperative recurrence is also a big issue. 10 The quality of life and productivity of IBD patients are severely affected. 11,12 In addition, IBD patients need lifelong medication and repeated hospitalizations, which also add significant social and economic burdens. IBD is increasingly becoming a global health burden. 5,13 Although the causes are not very clear, the incidence of IBD is closely related to the national or regional economy, industrial development level, and people's living habits. 14 China is the world's largest developing country and has experienced a great social and economic transformation over the past 30 years, from 1990 to 2019. In China, the epidemiology of IBD has also shifted. However, pertinent studies and data are scarce, which brings great difficulties to the prevention and treatment of the disease as well as the formulation of relevant medical policie -Abstract Truncated-
public, environmental & occupational health